MetaCap

Lisata Therapeutics (LSTA) vs Oragenics (OGEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Oragenics is the larger company by market cap ($708,377 vs $647,451), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LSTA-23.17%OGEN-68.59%
+13%-30%-72%
Oct 7, 20261 yearNov 20, 2026
LSTA-15.20%OGEN-65.57%
+18%-26%-70%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LSTA versus OGEN key metrics
MetricLSTAOGEN
Share price$0.8989$0.157
Market cap$647.45K$708.38K
1-day change-1.22%-8.72%
YTD return-51.67%—
1-year return-54.14%—
5-year return-93.89%—
EPS (TTM)$-28.20$-1.05
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$170.00K—
Revenue growth (YoY)-83.00%—
Net income (latest FY)$-16.59M$-9.84M
Operating margin-10711.18%—
Net margin-9756.47%—
52-week high$76.05$1.11
52-week low$0.85$0.13
Distance from 52-week high-98.82%-85.86%
Analyst consensusnone—
Average volume13.46K849.30K
Shares outstanding720.27K4.51M
Employees213
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Lisata Therapeutics

LSTA stock →

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

About Oragenics

OGEN stock →

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

LSTA vs OGEN FAQ

Which is bigger, Lisata Therapeutics or Oragenics?

Oragenics (OGEN) is larger, with a market capitalization of $708.38K compared with $647.45K for Lisata Therapeutics (LSTA).

Are Lisata Therapeutics and Oragenics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons